7 research outputs found
Treatment failure and risk and incidence of recurrent parasitaemia.
<p>Treatment failure and risk and incidence of recurrent parasitaemia.</p
Cumulative risk of <i>P</i>. <i>vivax</i> recurrence in all four treatment arms over the entire follow-up time.
<p>AL, artemether-lumefantrine; AL+PQ, artemether-lumefantrine + primaquine; CQ, chloroquine; CQ+PQ, chloroquine + primaquine.</p
Baseline characteristics of the study population.
<p>Baseline characteristics of the study population.</p
CONSORT flowchart of patient allocation for the day 42 outcome.
<p>AL, artemether-lumefantrine; AL+PQ, artemether-lumefantrine + primaquine; CQ, chloroquine; CQ+PQ, chloroquine + primaquine; G6PD, glucose-6-phosphate dehydrogenase; Lost, lost to follow-up.</p
Parasite and fever clearance by treatment arm.
<p>Parasite and fever clearance by treatment arm.</p
Histogram of the distribution of the number of recurrent <i>P</i>. <i>vivax</i> infections occurring during the 1-y follow-up period.
<p>AL, artemether-lumefantrine; AL+PQ, artemether-lumefantrine + primaquine; CQ, chloroquine; CQ+PQ, chloroquine + primaquine.</p